Search

Displaying results 3021 - 3030 of 10000 in total
  1. Drug

    Almitrine

    go.drugbank.com/drugs/DB01430
    Approved

    It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep. … It is used in the treatment of chronic obstructive pulmonary disease.

  2. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733] … Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals.

  3. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.

    Categories: Programmed Death Receptor-1 Blocking Antibody
  4. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    adherence to prophylaxis. … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  5. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body. … It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … alfa], to counter the decrease in endogenous EPO production.

  7. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    Since they inhibit these mechanisms and desensitize neuronal circuits, the use of CGRP receptor antagonists is beneficial in the treatment of migraine. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  8. Drug

    Certoparin

    go.drugbank.com/drugs/DB09261
    Approved

    Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.

  9. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

  10. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. … [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists